Modification of ChPL (chitosan protein–lipid) nanoparticles for in vitro release of rifampicin (RIF)
During recent years, the implication of nanoparticles (NPs) as drug delivery systems has gained much scientific attention. As drugs do not deliver themselves, a nanoparticle can act by optimizing drug delivery in the right place, at the right time and at the right dosage. In previous years, this res...
Main Authors: | Poopak Farnia, Jalaledin Ghanavi, Saeed Mollaei, Afshin Bahrami, Ali Akbar Velayati |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2015-01-01
|
Series: | International Journal of Mycobacteriology |
Subjects: | |
Online Access: | http://www.ijmyco.org/article.asp?issn=2212-5531;year=2015;volume=4;issue=5;spage=16;epage=16;aulast=Farnia;type=0 |
Similar Items
-
An evaluation of false-positive rifampicin resistance on the Xpert MTB/RIF
by: Yeliz Tanriverdi Cayci, et al. -
PL Tunable GaN Nanoparticles Synthesis through Femtosecond Pulsed Laser Ablation in Different Environments
by: Juan Hao, et al.
Published: (2020-02-01) -
Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis
by: Kaican Zong, et al.
Published: (2019-08-01) -
Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China
by: Zheyuan Wu, et al.
Published: (2020-02-01) -
3PL, 4PL and insourcing logistics
by: Mauro Vivaldini
Published: (2015-12-01)